(29 days)
Not Found
No
The summary describes a navigation and mapping system based on magnetic sensor and ACL technology, image integration (CT, MRI, ICE), and real-time signal processing. There is no mention of AI or ML algorithms being used for analysis, mapping, or navigation.
No.
The device is a mapping and navigation system that provides diagnostic information for cardiac procedures, rather than directly treating a condition.
Yes.
The device is intended for mapping and display of various cardiac information (e.g., electrical activation, propagation, potential, impedance, geometry, and ECG fragmentation maps), and real-time display of patient signals (ECG and intracardiac electrograms), which are all forms of diagnostic data by analyzing cardiac function.
No
The device description explicitly states it is a "catheter-based atrial and ventricular mapping system" that uses "a specialized mapping catheter and reference device" and "two distinct types of location technology - magnetic sensor technology and Advanced Catheter Location (ACL) technology." This indicates the system includes significant hardware components beyond just software.
Based on the provided information, the CARTO® 3 V2.0 System is not an In Vitro Diagnostic (IVD) device.
Here's why:
- IVD devices are used to examine specimens derived from the human body (like blood, urine, tissue) outside of the body. They are used to provide information about a physiological state, health, or disease.
- The CARTO® 3 V2.0 System is used within the human body. It is a catheter-based system for mapping the electrical activity and anatomy of the heart in real-time during a medical procedure. It acquires signals directly from within the patient.
The device description and intended use clearly indicate that it is an in vivo (within the living body) medical device used for navigation and mapping during electrophysiology procedures.
N/A
Intended Use / Indications for Use
The CARTO® 3 V2.0 System is intended for catheter-based atrial and ventricular mapping. The mapping system allows real-time display of cardiac maps in a number of different formats. Maps may be displayed as anatomical maps, cardiac electrical activation maps, cardiac electrical propagation maps, cardiac electrical potential maps, impedance maps, cardiac chamber geometry maps and ECG fragmentation maps. The acquired patient signals, including body surface ECG and intracardiac electrograms may also be displayed in real time on the System's display screen. The CARTO® 3 V2.0 System is also intended to support EP procedures, maintaining CARTO® System capabilities, in the presence of a high metallic environment and magnetic field strengths up to 0.1 T and provide a data communication channel to the Stereotaxis Niobe® Catheter Navigation System. The CARTO® 3 V2.0 System includes CARTOMERGE® Plus functionality to import, register and merge CT or MRI structural images with CARTO® map's physiological information and real time catheter navigation. The system includes the Fast Anatomical Mapping (FAM) functionality that allows for the quick creation of cardiac anatomical volumes using catheters with magnetic location sensors. The system's CARTOSOUND™ image integration functionality enables integration of intracardiac echo (ICE) to enable visualization of 3D combined maps. In addition to the use of specialized navigation catheters with magnetic location sensors, the system is also intended for use with conventional, non-navigational, electrophysiology catheters without magnetic location sensors.
Product codes
DQK
Device Description
The CARTO® 3 V2.0 EP Navigation System is a catheter-based atrial and ventricular mapping system designed to acquire and analyze data points, and use this information to display 3D anatomical and electroanatomical maps of the human heart in real-time. The location information needed to create the cardiac maps and the local elector mans are acquired using a specialized mapping catheter and reference device. The system allows real-time display of electrograms and cardiac maps based on the received intra cardiac signals from the catheters in a number of different formats. The acquired patient signals, including body surface ECG and intracardiac electrograms (IECG) may also be displayed on the display screen. The CARTO® 3 V2.0 System uses two distinct your of location technology - magnetic sensor technology and Advanced Catheter Location (ACL) technology.
Mentions image processing
Yes
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
CT or MRI structural images, intracardiac echo (ICE)
Anatomical Site
Human heart
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
The CARTO® 3 V2.0 EP Navigation System underwent extensive Bench and Animal Testing to verify the modified features and to demonstrate with regression testing that the new features did not negatively affect existing features. The CARTO® 3 V2.0 EP Navigation System passed all tests in accordance with appropriate test criteria and standards, and the modified device did not raise new questions of safety or effectiveness.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s)
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 870.1425 Programmable diagnostic computer.
(a)
Identification. A programmable diagnostic computer is a device that can be programmed to compute various physiologic or blood flow parameters based on the output from one or more electrodes, transducers, or measuring devices; this device includes any associated commercially supplied programs.(b)
Classification. Class II (performance standards).
0
K103746 ャリタ
15 510(K) SUMMARY
15.1 General Information
Applicant:
Biosense Webster, Inc. 3333 Diamond Canyon Road Diamond Bar, CA 91765 USA Phone: 909-839-8597 Fax: 909-839-8804
Date:
December 22, 2010.
Wayne R. Hohman
Contact Person:
Trade/Proprietary Device Name: Manufacturing Part Numbers:
Common Device Name:
Classification Name:
Predicate Devices:
Manufacturing Facilities:
Project Manager Regulatory Affairs
CARTO® 3 V2.0 EP Navigation System and Accessories FG-5400-00 (with standard location pad) FG-5600-00 (with RMT location pad)
Cardiac mapping system
Programmable diagnostic computer Class II, 21 CFR 870.1425 Product Code DQK
CARTO® 3 V1.05 EP Navigation System and Accessories (519(k) K093455) Ensite Velocity™ System (510(k) K101328)
:
Biosense Webster (Israel) Ltd. a Johnson & Johnson Company 4 Hatnufa Street, POB 275 Yokneam 20692 Israel
1
15.2 Substantial Equivalence
The CARTO 3 EP Navigation System, Version 2.0, is substantially equivalent to the legally marketed CARTO 3 EP Navigation System, Version 1.05, and a second predicate device as shown in the Table below:
| Predicate Devices for CARTO® 3 EP Navigation System, Version 2.0 | ||
|---|---|---|
| Submission Name | 510(k) | |
| Number | Equivalence Criteria | |
| CARTO® 3 V1.05 EP | ||
| Navigation System | K093455 | FDA cleared version of CARTO®3 |
| EP Navigation System prior to | ||
| Version 2.0. | ||
| Ensite Velocity™ System | K101328 | St. Jude Medical device |
15.3 Description of Device
The CARTO® 3 V2.0 EP Navigation System is a catheter-based atrial and ventricular mapping system designed to acquire and analyze data points, and use this information to display 3D anatomical and electroanatomical maps of the human heart in realitime. The location information needed to create the cardiac maps and the local elector mans are acquired using a specialized mapping catheter and reference device. The system allows real-time display of electrograms and cardiac maps based on the received intra cardiac signals from the catheters in a number of different formats. The acquired patient signals, including body surface ECG and intracardiac electrograms (IECG) may also be displayed on the display screen. The CARTO® 3 V2.0 System uses two distinct your of location technology - magnetic sensor technology and Advanced Catheter Location (ACL) technology.
15.4 Indications for Use
The Indications for Use for the modified device are identical to the predicate device:
The CARTO® 3 V2.0 System is intended for catheter-based atrial and ventricular mapping. The mapping system allows real-time display of cardiac maps in a number of different formats. Maps may be displayed as anatomical maps, cardiac electrical activation maps, cardiac electrical propagation maps, cardiac electrical potential maps, impedance maps, cardiac chamber geometry maps and ECG fragmentation maps. The acquired patient signals, including body surface ECG and intracardiac electrograms may also be displayed in real time on the System's display screen. The CARTO® 3 V2.0 System is also intended to support EP procedures, maintaining CARTO® System capabilities, in the presence of a high metallic environment and magnetic field strengths up to 0.1 T and provide a data communication channel to the Stereotaxis Niobe® Catheter Navigation System. The CARTO® 3 V2.0 System includes CARTOMERGE® Plus functionality to import, register and merge CT or MRI structural images with CARTO® map's physiological information and real time catheter navigation. The system
Biosense Webster, Inc. CARTO 3 v 2.0 Special 510(k)
2
includes the Fast Anatomical Mapping (FAM) functionality that allows for the quick creation of cardiac anatomical volumes using catheters with magnetic location sensors. The system's CARTOSOUND™ image integration functionality enables integration of intracardiac echo (ICE) to enable visualization of 3D combined maps. In addition to the use of specialized navigation catheters with magnetic location sensors, the system is also intended for use with conventional, non-navigational, electrophysiology catheters without magnetic location sensors.
15.5 Summary of Non-clinical Performance Testing
The CARTO® 3 V2.0 EP Navigation System underwent extensive Bench and Animal Testing to verify the modified features and to demonstrate with regression testing that the new features did not negatively affect existing features. The CARTO® 3 V2.0 EP Navigation System passed all tests in accordance with appropriate test criteria and standards, and the modified device did not raise new questions of safety or effectiveness.
15.6 Conclusions
The Bench and Animal Non-clinical Testing demonstrated that the CARTO® 3 V2.0 EP Navigation System is as safe, as effective, and performs as well as or better than the predicate devices. This testing program supports the determination of substantial equivalence to the predicate devices. . . . .
3
Image /page/3/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a stylized eagle with three lines forming its body and wings. The eagle's head is facing left. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES USA" is arranged in a circular pattern around the eagle.
Food and Drug Administration 10903 New Hampshire Avenue Document Control Room-WO66-G609 Silver Spring, MD 20993-0002
Biosense Webster, Inc. c/o Mr. Wayne R. Hohman Project Manager Regulatory Affairs 3333 Diamond Canyon Road Diamond Bar, CA 91765
JAN 2 1 201
Re: K103746
CARTO® 3 V2.0 EP Navigation System Regulatory Number: 21 CFR 870.1425 Regulation Name: Programmable Diagnostic Computer Regulatory Class: II (two) Product Code: 74 DQK Dated: December 22, 2010 Received: December 23, 2010
Dear Mr. Hohman:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA), You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
4
Page 2 - Mr. Wayne R. Hohman
Please be advised that I'DA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/Resourcesfor You/Industry/default.htm.
Sincerely yours,
W.R.M.
Bram D. Zuckerman, M.D. Director Division of Cardiovascular Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
5
INDICATIONS FOR USE 5
510(k) No (if known):
Device Name: CARTO® 3 V2.0 EP Navigation System
Indications for Use:
The CARTO® 3 V2.0 System is intended for catheter-based atrial and ventricular mapping. The mapping system allows real-time display of cardiac maps in a number of different formats. Maps may be displayed as anatomical maps, cardiac electrical activation maps, cardiac electrical propagation maps, cardiac electrical potential maps, impedance maps, cardiac chamber geometry maps and ECG fragmentation maps. The acquired patient signals, including body surface ECG and intracardiac electrograms may also be displayed in real time on the System's display screen. The CARTO® 3 2.0 System is also intended to support IP procedures, maintaining CARTO® System capabilities, in the presence of a high metallic. environment and magnetic field strengths up to 0.1 T and provide a data communication channel to the Stereotaxis Niobe Catheter Navigation System. The CARTO® 3 V2.0 System includes CARTOMERGE® PLUS functionality to import, register and merge CT or MRI structural images with CARTO® map's physiological information and real time catheter navigation. The system includes the Fast Anatomical Mapping (FAM) functionality that allows for the quick creation of cardiac anatomical volumes using catheters with magnetic location sensors. The system's CARTOSOUND™ image integration functionality enables integration of intracardiac echo (ICE) to enable visualization of 3D combined maps. In addition to the use of specialized navigation catheters with magnetic location sensors, the system is also intended for use with conventional, non-navigational, electrophysiology catheters without magnetic location sensors.
Prescription Use 2 (Part 21 CFR 801 Subpart D)
AND/OR
Over-The-Counter Use (21 CFR 801 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
(Division Sign-Off) Division of Cardiovascular Devices
Page 1 of 1
510(k) Number k(08746
Biosense Webster, Inc. CARTO 3 v 2.0 Special 510(k)
Page 35 of 567